S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
advanced high risk prostate cancer: preliminary results of a prospective phase II study. Int J
Hyperthermia 2007;23(5):451-6. http://www.ncbi.nlm.nih.gov/pubmed/17701536
283. Algan O, Fosmire H, Hynynen K, Dalkin B, Cui H, Drach G, Stea B, Cassady JR. External beam
radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate
carcinoma. Cancer 2000;89(2):399-403. http://www.ncbi.nlm.nih.gov/pubmed/10918172
284. Bolla M, Van Poppel H, Collette L, van Cangh P, Vekemans K, Da PL, de Reijke TM, Verbaeys
A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K, Pierart M.
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial
(EORTC trial 22911). Lancet 2005;366(9485):572-8.
http://www.ncbi.nlm.nih.gov/pubmed/16099293
285. Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD,
Thompson IM, Crawford ED. The prognostic impact of seminal vesicle involvement found at
prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group
8794. J Urol 2008;180(6):2453-7. http://www.ncbi.nlm.nih.gov/pubmed/18930488
286. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J,
Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological
T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival:
long-term followup of a randomized clinical trial. J Urol 2009;181(3):956-62.
http://www.ncbi.nlm.nih.gov/pubmed/19167731
287. van der Kwast TH, Bolla M, Van Poppel H, van Cangh P, Vekemans K, Da PL, Bosset JF, Kurth
KH, Schroder FH, Collette L. Identification of patients with prostate cancer who benefit from
immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25(27):4178-86.
http://www.ncbi.nlm.nih.gov/pubmed/17878474
288. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A,
Souchon R, Stockle M, Rube C, Weissbach L, Althaus P, Rebmann U, Kalble T, Feldmann HJ,
Wirth M, Hinke A, Hinkelbein W, Miller K. Phase III postoperative adjuvant radiotherapy after
radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer
with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2009;27(18):2924-30. http://www.ncbi.nlm.nih.gov/pubmed/19433689
289. Thompson IM, Jr., Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J,
Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically
advanced prostate cancer: a randomized clinical trial. JAMA 2006;296(19):2329-35.
http://www.ncbi.nlm.nih.gov/pubmed/17105795
290. Collette L, Van Poppel H, Bolla M, van Cangh P, Vekemans K, Da PL, de Reijke TM, Verbaeys
A, Bosset JF, Pierart M. Patients at high risk of progression after radical prostatectomy: do
they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J
Cancer 2005;41(17):2662-72. http://www.ncbi.nlm.nih.gov/pubmed/16223581
291. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ,
Zincke H. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive
surgical margin. Journal of Urology 2000;163(4):1178-82.
http://www.ncbi.nlm.nih.gov/pubmed/10737490
292. Swanson GP, Thompson IM, Basler J. Treatment options in lymph node-positive prostate
cancer. Cancer 2006;106(12):2531-9. http://www.ncbi.nlm.nih.gov/pubmed/16700035
293. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of
progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-
7. http://www.ncbi.nlm.nih.gov/pubmed/10235151
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011